Considering the effects of the only currently available targeted therapy patients with genetic obesity, setmelanotide, liraglutide (−4.7%) and naltrexone-bupropion (−5.2%) could be considered relatively less effective compared to setmelanotide at 12 weeks of treatment (−4.2 to −16% in patients with BBS, LEPR deficiency and POMC/PCSK1 deficiency).12 The gene discussed is POMC; the disease is Genetic obesity.